A month after disclosing positive top-line Phase II/III data with its compound for chronic myeloid leukemia (CML), ChemGenex Pharmaceuticals Ltd. is spinning out its efforts in diabetes and obesity in favor of the cancer push. (BioWorld Today) Read More
